Will the FDA approve any psychedelic substance for medical use before 2027?
Yes refers to: Any psychedelic substance for medical use
Short Answer
Both the model and the market expect the FDA to approve any psychedelic substance for medical use before 2027, with no compelling evidence of mispricing.
1. Executive Verdict
- Compass Pathways targets a late 2026 FDA decision for COMP360 psilocybin.
- The FDA declined MDMA approval, shifting focus to COMP360 psilocybin.
- Psychopharmacologic Drugs Advisory Committee remains cautious on novel psychiatric drugs.
- DEA rescheduling introduces significant delays after any FDA psychedelic approval.
- COMP360's proposed REMS is crucial for anticipated FDA approval by mid-2027.
- Positive long-term durability data from COMP006 is expected in early Q3 2026.
Who Wins and Why
| Outcome | Market | Model | Why |
|---|---|---|---|
| Any psychedelic substance for medical use | 24.0% | 24.5% | Positive Phase 3 clinical trial data for MDMA and psilocybin could lead to FDA approval. |
Current Context
Psychedelic substances are nearing FDA approval, driven by recent positive trial data. Compass Pathways' synthetic psilocybin, COMP360, has shown promising results in treating Treatment-Resistant Depression (TRD), with positive outcomes from its first Phase 3 trial (COMP005) in Q2 2025 and its second pivotal Phase 3 trial (COMP006) on February 17, 2026 [^]. The COMP006 trial demonstrated significant reductions in depression symptoms at Week 6 [^]. Following these results, Compass Pathways plans a "rolling submission" of its New Drug Application (NDA) for COMP360, expected to conclude in the fourth quarter of 2026, with a potential approval decision in early 2027 [^]. Additionally, in February 2026, the FDA accepted an Investigational New Drug (IND) application for COMP360 for Post-Traumatic Stress Disorder (PTSD), enabling a Phase 2b/3 clinical trial [^]. New research also suggests that psychedelics may contribute to brain myelin repair, potentially aiding long-term recovery in conditions like PTSD [^]. Despite a recommendation from FDA Commissioner Marty Makary for fast-tracking, White House officials reportedly blocked COMP360 from the FDA's new National Priority Voucher pilot program on March 5, 2026 [^]. Industry analysts view 2026 as a pivotal year for psychedelics, anticipating rapid and durable efficacy from these substances [^].
FDA approval faces significant hurdles, including trial design and data clarity. The FDA emphasizes the need for robust efficacy and safety data from late-stage clinical trials, with longer-term durability data from COMP006 (26 weeks) expected in early Q3 2026 [^]. A primary concern revolves around the "functional unblinding" of trials, where participants may easily discern if they received the active psychedelic or a placebo due to the drug's psychoactive effects [^]. The FDA recommends appropriate control groups, possibly using sub-perceptual doses or other psychoactive drugs to mimic effects [^]. Another critical data point is clarifying the specific contribution of the psychedelic substance versus the accompanying psychotherapy, particularly when psychotherapy is used in both treatment and control arms [^]. Some companies are exploring trial designs that exclude intensive psychotherapy to address these regulatory challenges [^]. FDA officials, including Dr. Tiffany Farchione, have stressed the importance of rigorous study designs to produce interpretable results that can support drug applications [^]. The August 2024 rejection of Lykos Therapeutics' MDMA application for PTSD served as a significant setback, underscoring the FDA's stringent requirements regarding trial design, unblinding, efficacy, safety, and potential misconduct, leading to requests for additional Phase 3 studies for MDMA [^].
Beyond efficacy, challenges include safety, access, and infrastructure development. Ongoing questions concern the long-term safety of psychedelics, their potential for abuse, and the risk of negative psychological reactions such as anxiety or psychosis [^]. The high cost of psychedelic treatments, coupled with the necessity for close supervision and guided sessions, raises concerns about equitable access, particularly without comprehensive insurance coverage [^]. There are also challenges in establishing a sufficient number of competent professionals adequately trained and supervised to administer complex psychedelic-assisted therapy regimens [^]. Commercialization efforts face additional hurdles, including navigating reimbursement procedures and overall costs [^]. Patients and therapists also seek guidance on potential interactions between psychedelics and other medications like SSRIs or MAOIs [^]. Looking ahead, MindMed's LSD program (MM120) for generalized anxiety disorder and major depressive disorder anticipates Phase 3 data in late 2026 [^]. Beckley Psytech and Atai Life Sciences expect to initiate Phase 3 trials for BPL-003 (intranasal 5-MeO-DMT) in Q2 2026, pending FDA alignment [^]. The 6th Annual Psychedelic Therapeutics & Drug Development Conference on February 26-27, 2026, will address R&D challenges and regulatory progress [^]. Even with FDA approval, psychedelics would require rescheduling from Schedule I by the Drug Enforcement Administration (DEA), and individual states would need to update their laws [^].
2. Market Behavior & Price Dynamics
Historical Price (Probability)
Outcome probability
Date
This prediction market has demonstrated a consistent and clear downward trend, with the probability of a "YES" outcome declining from a high of 35% to its current price of 24%. The market opened with moderate optimism at 32% but has since established a bearish pattern. Key price levels include the peak resistance around $0.35 and a floor of support near the all-time low of $0.21. The current price is trading near this support level, indicating that pessimism has become entrenched. The total volume of over 32,000 contracts suggests a liquid market where this downward trend is supported by significant trading activity, reflecting a growing conviction among participants.
The primary driver of this bearish price action appears to be the clarification of the regulatory timeline for Compass Pathways' COMP360, the leading drug candidate. Despite overwhelmingly positive Phase 3 trial results announced in February 2026, the price has continued to fall. This seemingly counterintuitive movement is explained by the company's stated plan to complete its New Drug Application (NDA) submission in the fourth quarter of 2026. The subsequent FDA review process would push a potential approval decision into early 2027. Since the market resolves based on an approval "before 2027," this timeline makes a "YES" resolution highly improbable.
The market sentiment is not a reflection on the likelihood of eventual approval but rather a direct bet on the timing. The downward trend indicates that traders have priced out the possibility of an accelerated review and are now operating under the assumption that the standard regulatory process will not conclude before the December 31, 2026 deadline. The price has stabilized at 24%, suggesting the market assigns a low but non-zero probability to an unexpectedly fast approval, while the overwhelming consensus points toward a "NO" resolution based on the publicly available timeline.
3. Market Data
Contract Snapshot
A YES resolution occurs if the FDA approves any psychedelic substance for medical use by the end of 2026. A NO resolution occurs if the FDA does not approve any such substance for medical use by this deadline. No other specific settlement conditions or key dates are detailed in the provided content.
Available Contracts
Market options and current pricing
| Outcome bucket | Yes (price) | No (price) | Last trade probability |
|---|---|---|---|
| Any psychedelic substance for medical use | $0.25 | $0.76 | 24% |
Market Discussion
Discussions regarding the potential FDA approval of psychedelic substances for medical use before 2027 are characterized by cautious optimism tempered by recent setbacks [^]. Many experts and companies anticipate that psilocybin-based therapies for treatment-resistant depression and LSD for generalized anxiety disorder could receive FDA approval, with New Drug Application submissions expected in late 2026 or early 2027 and potential approvals shortly thereafter [^]. However, the recent rejection of MDMA for PTSD highlights significant regulatory hurdles, including challenges in trial design, such as maintaining blinding and effectively integrating psychotherapy, despite some perceived political support and "Breakthrough Therapy" designations for several psychedelic compounds [^].
4. When Will COMP360 Psilocybin Receive FDA Approval?
| Final Module Submission Deadline | March 31, 2026 [^][^] |
|---|---|
| Expected PDUFA Decision Date | September 30, 2026 [^][^] |
| COMP006 Durability Data Expectation | Q3 2026 [^][^] |
Compass Pathways aims for a late 2026 PDUFA decision. The company is pursuing a rolling New Drug Application (NDA) submission for COMP360 in treatment-resistant depression (TRD). The final Module 1 is targeted for submission by March 31, 2026, which is the pivotal date to initiate the FDA's 6-month Priority Review period [^][^][^][^]. This expedited review status is granted due to COMP360's Breakthrough Therapy Designation. If this deadline is met, a PDUFA decision could potentially occur by September 30, 2026, with Compass aiming for a market launch in late 2026 or early 2027 [^][^].
Durability data and manufacturing pose potential timeline challenges. A crucial component for the NDA is the 26-week durability results from the COMP006 Phase 3 trial, which are anticipated in Q3 2026. Delays in obtaining these results or any issues with their robustness could push the final module submission beyond March 31, 2026, thereby extending the PDUFA decision timeline into or beyond 2027 [^][^][^]. While early positive efficacy signals from the Phase 3 trial are encouraging [^], potential regulatory hurdles also include ensuring consistent manufacturing standards for this complex psychedelic drug.
Analysts express cautious optimism amid remaining timeline uncertainties. Analysts maintain cautious optimism, assigning a 60-40 chance of PDUFA clearance by Q3 2026 for early approval. However, there is an approximately 30% chance of a delayed 2027 approval due to potential process bottlenecks or regulatory challenges. The absence of publicly disclosed, module-by-module submission timelines from Compass Pathways also introduces a degree of uncertainty for market stakeholders [^].
5. Does COMP360 NDA Methodology Effectively Address Psychedelic Trial Bias?
| Phase 3 MADRS Score Reduction | 3.6- and 3.8-points at six weeks [^] |
|---|---|
| Suicidal Ideation Rate | Less than 1% of patients [^] |
| Sustained Response (6 months) | ~50% of responders [^] |
Compass Pathways implemented several methodological innovations in its COMP360 NDA to address critiques of functional unblinding. Key among these was the use of an active placebo, a psilocybin analog designed to mimic the physical sensations of the active drug, thereby reducing the risk of patients or clinicians inferring treatment assignment [^]. Furthermore, the trial leveraged Interactive Web Response Systems (IWRS) and Randomization and Trial Supply Management (RTSM) for real-time blinding verification, ensuring automated randomization and secure supply management to maintain blinding integrity throughout the trial [^].
Expectancy effects were addressed through statistical controls and objective measures. To combat these effects, Compass integrated baseline expectancy controls, including adjusted regression models with patient-reported expectations as covariates [^]. The study also employed objective biomarkers like fMRI activity patterns and neurotransmitter assays to provide quantifiable evidence independent of subjective bias [^]. A per-protocol analysis, which excluded self-unblinded patients, further confirmed that unblinding had minimal impact on overall efficacy.
The rigorous methodology supported significant efficacy and safety outcomes. The Phase 3 trials reported 3.6- and 3.8-point reductions in MADRS scores, which, while lower than Phase 2, were complemented by crucial 6-month durability data showing a sustained response in approximately 50% of responders [^]. The safety profile also reported less than 1% suicidal ideation across both treatment arms, directly addressing concerns raised in other psychedelic trials [^].
6. What are the PDAC's Current Stances on Novel Psychiatric Drug Approvals?
| MDMA for PTSD Efficacy Vote | 2–9 against [^] |
|---|---|
| MDMA for PTSD Net Benefits Vote | 1–10 against [^] |
| Next PTSD Treatments Meeting | July 18, 2025 [^] |
The Psychopharmacologic Drugs Advisory Committee (PDAC) demonstrates significant caution regarding novel psychiatric therapies. The committee recently rejected MDMA for PTSD in June 2024, voting 2–9 against efficacy and 1–10 against net benefits. Key concerns cited included abuse potential, inconsistent trial data, and inadequate risk mitigation strategies, particularly given MDMA's Schedule I status. This decision establishes a significant precedent, indicating high barriers for the approval of future psychedelic-based drug applications, even for severe conditions [^].
Regulatory trends emphasize rigorous scrutiny for therapies with abuse potential. While the FDA approved 22 novel psychiatric drugs between 2012 and 2024, including lofexidine for opioid withdrawal, therapies with abuse potential consistently face rigorous scrutiny, demanding robust efficacy evidence and stringent risk mitigation. The PDAC prioritizes risk aversion for high-abuse substances, demanding ironclad abuse mitigation plans and often criticizing adaptive trial designs for potential bias over therapeutic expediency NIH FDA PDAC Page" target="_blank" rel="nofollow noopener noreferrer" class="citation-link" title="[^].
Future psychedelic FDA approvals face substantial hurdles before 2027. Given the recent MDMA rejection and the committee’s current focus on non-psychedelic solutions for the upcoming July 2025 PTSD meeting, the likelihood of new psychedelic FDA approvals before 2027 remains low to moderate. Potential pathways for approval would necessitate major regulatory shifts, such as Schedule reclassification, or significant innovations in trial methodologies, including the use of digital biomarkers and real-world data to bolster efficacy claims and address biases inherent in traditional designs NIH FDA PDAC Page" target="_blank" rel="nofollow noopener noreferrer" class="citation-link" title="[NIH FDA PDAC Page](">[^].
7. When Will Psilocybin Be Medically Available After FDA Approval?
| Typical DEA Rescheduling Timeline | 6-30 months post-HHS recommendation [^][^] |
|---|---|
| Marijuana Rescheduling Duration | 3.5 years from directive to NPRM, unresolved as of March 2026 [^] |
| Projected Psilocybin Medical Availability | Delayed until January 2028 or later [^] |
The DEA's drug rescheduling process is complex and often faces significant delays. The agency's process under the Controlled Substances Act requires coordination with the Department of Health and Human Services (HHS), which includes an evaluation of factors such as abuse potential and medical utility [^]. For new FDA-approved drugs, a specific provision, §811(j), mandates the DEA to issue a 90-day Interim Final Rule (IFR) after receiving both an HHS recommendation and FDA approval [^]. However, bureaucratic hurdles, including high volumes of public comments and potential legal challenges, frequently cause substantial delays, extending typical timelines from 6 to 30 months following an HHS recommendation [^][^].
Precedent cases reveal the potential for extended administrative delays in rescheduling substances. For instance, the New Drug Application (NDA) for MDMA-assisted therapy received a Complete Response Letter (CRL) in 2024, pushing its FDA approval and subsequent DEA rescheduling efforts to late 2025 at the earliest [^]. Similarly, the rescheduling of marijuana, initiated by a 2022 Executive Order, has encountered 3.5 years of delays due to inter-agency friction and legal challenges, remaining unresolved as of March 2026 [^].
Therefore, psilocybin's medical availability will likely be delayed beyond 2026. Even with a potential FDA approval for psilocybin by mid-2026, for trials such as those conducted by Compass Pathways, the DEA rescheduling process is expected to extend beyond mid-2027 [^][^]. HHS evaluations alone can take 12 to 18 months post-NDA submission, pushing the DEA's IFR issuance well into 2027 [^][^]. When coupled with the DEA's historical delays, such as the 10 years taken for hydrocodone rescheduling, full medical availability of psilocybin could be delayed until January 2028 or later, notwithstanding some states exploring parallel access tracks [^][^][^].
8. How Does Compass Pathways' REMS Enhance COMP360 FDA Approval?
| NDA Submission Plan | Q4 2026 [^] |
|---|---|
| GlobalData Sales Forecast | $879 million by 2031 [^] |
| DEA Rescheduling Duration | Up to 90 days [^] |
Compass Pathways' proposed REMS for COMP360 therapy sets rigorous standards. This program is crucial for its anticipated FDA approval by mid-2027 [^]. It emphasizes stringent therapist certification, requiring mandatory theoretical and experiential training, similar to the Spravato program [^]. The REMS also mandates treatment in certified, audited healthcare facilities equipped with mental health stabilization resources, contrasting with Lecanemab's rejected REMS, which lacked enforceable site standards [^]. Patient monitoring protocols include pre- and post-dosing assessments, with outcomes and adverse events tracked in real-time via a proprietary electronic health record (EHR) system [^].
Compass's REMS specifically addresses past FDA rejections. This framework stands out compared to previously rejected programs such as Zuranolone (SAGE-717) and Lecanemab (Leqembi). Zuranolone's REMS was deemed insufficient due to a lack of robust therapist training and the absence of independent audits for pharmacies [^]. Lecanemab's REMS failed to mandate real-time monitoring for critical risks and suffered from inconsistent clinic certification [^]. In contrast, Compass's framework incorporates structured, hands-on therapist training [^], transparent third-party site audits [^], and real-time safety monitoring through EHR integration, directly addressing past criticisms of delayed reporting [^].
The comprehensive REMS strengthens COMP360's path to FDA approval. This proactive and thorough approach aligns with FDA preferences for robust risk mitigation, making approval highly probable by late 2026 or early 2027 [^]. The drug benefits from an accelerated approval pathway, reinforced by its Breakthrough Therapy status and a rolling New Drug Application (NDA) submission [^]. This is further supported by strong Phase III trial data, which indicates significant improvements in remission rates [^]. Additionally, the existing network of interventional psychiatry clinics, established by Spravato [^], provides a ready infrastructure for COMP360. However, potential delays in DEA rescheduling from Schedule I to IV and unresolved reimbursement challenges could still impact commercialization efforts beyond 2027 [^].
9. What Could Change the Odds
Key Catalysts
The prediction market's outcome hinges primarily on the progress of investigational psychedelic-assisted therapies currently in late-stage clinical trials [^] . The most advanced candidates were MDMA for PTSD and psilocybin for Treatment-Resistant Depression (TRD). A significant bearish catalyst has already occurred with the FDA's decline of MDMA approval in August 2024, requesting additional clinical trial data. This development diminishes the chance of MDMA approval before 2027 and shifts focus heavily to Compass Pathways' COMP360 psilocybin.
Key bullish catalysts for COMP360 psilocybin include positive long-term durability data from the COMP006 Phase 3 trial, expected in early Q3 2026. A formal New Drug Application (NDA) submission for COMP360 by Q4 2026, coupled with an expedited review due to its Breakthrough Therapy Designation, could theoretically lead to approval before January 1, 2027 [^]. A positive FDA advisory committee recommendation, unexpected fast-tracking, or favorable FDA statements would also boost the "YES" outcome. Positive Phase 3 results from other substances like MindMed's MM120 or Cybin's CYB003, expected in mid to late 2026, could also contribute to a more supportive regulatory environment.
Conversely, bearish catalysts for COMP360 include negative or inconclusive long-term data from its COMP006 trial or delays in its NDA submission beyond Q4 2026. An extended FDA review period, typically 6-10 months or longer, for an NDA submitted in Q4 2026 would almost certainly push a decision into mid-2027 or later, falling outside the market's timeframe. An FDA advisory committee rejection for COMP360 or the emergence of significant new safety concerns across any leading psychedelic candidates could also hinder approval [^]. Increased regulatory scrutiny, beyond the FDA's June 2023 draft guidance on psychedelic clinical trials, also poses a risk.
Key Dates & Catalysts
- Expiration: January 08, 2027
- Closes: January 01, 2027
10. Decision-Flipping Events
- Trigger: The prediction market's outcome hinges primarily on the progress of investigational psychedelic-assisted therapies currently in late-stage clinical trials [^] .
- Trigger: The most advanced candidates were MDMA for PTSD and psilocybin for Treatment-Resistant Depression (TRD).
- Trigger: A significant bearish catalyst has already occurred with the FDA's decline of MDMA approval in August 2024, requesting additional clinical trial data.
- Trigger: This development diminishes the chance of MDMA approval before 2027 and shifts focus heavily to Compass Pathways' COMP360 psilocybin.
12. Historical Resolutions
No historical resolution data available for this series.
Get Real-Time Research Updates
Sign up for early access to live reports, historical data, and AI-powered market insights delivered to your inbox.
